Paratek's Omadacycline Development May Hinge On Moxifloxacin Mortality
Executive Summary
If moxifloxacin, the comparator in omadacycline's CABP trial, is thought to have an unusually low mortality rate, then the mortality imbalance seen between arms in the study may not seem so worrying.